

Form PTO-892 U.S. Department of Commerce	Serial Number 09/363,748	Group Art Unit 1623	Attachment to Paper Number 20
Notice of References Cited	APPLICANT(S) Watkins et al.		

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	5 5 8 3 1 1 7	12/10/96	von Borstel et al.	514	050.000	
*	B	5 9 6 2 4 5 9	10/06/00	Piazza et al.	514	269.000	

Foreign Patent Documents


*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	L	0 1 7 8 2 6 7	04/16/86	Europe(EPO)	Polifarma SpA	-----	-----		
*	M	8 9 0 3 8 3 7	05/05/89	World(PCT/WO)	Proneuron, Inc.	-----	-----		
*	N	9 7 4 3 8 9 9	11/27/97	World(PCT/WO)	Breonics, Inc.	-----	-----		
*	O	9 7 4 5 1 2 7	12/04/97	World(PCT/WO)	Poliframa, SpA	-----	-----		
*	P††	7 2 1 5 8 7 9	08/15/95	Japan(JPO)	Otsuka Selyaku	-----	-----		

†† English Abstract included.

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	R	Page et al., "Developmental Disorder Associated with Increased Cellular Nucleotidase Activity," <u>Proceedings of the National Academy of Sciences USA</u> , 94(21), 11601-11606 (October 14, 1997).
*	S	Coirault et al., "Uridine 5-Triphosphate in Therapy. I. Cure of Neurogenic Muscular Atrophy," <u>Presse Med.(Fr.)</u> , 68, 1127-1129 (1960); <u>Chemical Abstracts</u> , 57(7), p. 73, Abstract No. 10485f (October 1, 1962); only Abstract supplied.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. Eric Crane 	DATE 11/26/01	page 1 of 3 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number 09/363,748	Group Art Unit 1623	Attachment to Paper Number	20
Notice of References Cited	APPLICANT(S)			
	Watkins et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* T†	Merlini et al., "Effects of Large Doses of Pyrimidine Nucleosides Cytidine and Uridine in Elderly Patients with Neuropsychological Disturbances Caused by Vascular and Cerebral Metabolic Insufficiency," <u>Gazz. Med. Ital. Arch. Sci. Med.</u> , <u>145</u> (6), 379-390 (1966); <u>Biological Abstracts</u> , <u>83</u> , Abstract No. 27367 (1987); only Abstract supplied.
* U†	Gallai et al.(I), "Effects of Uridine in the Treatment of Diabetic Neuropathy An Electrophysiological Study," <u>Acta Neurol. Scand.</u> , <u>86</u> (1), 3-7 (1992); <u>Biological Abstracts</u> , <u>94</u> , Abstract No. 112030 (1992); only Abstract supplied.
* V†	Gallai et al.(II), "Multi-Infarct Dementia: Modification of the P300 Cognitive Event-Related Potential in Patients Treated with the Association of Cytidine and Uridine," <u>Rivista di Neuropsichiatria e Science Affini</u> , <u>41</u> (1), 1-9 (1995); <u>BIOSIS</u> , <u>1996</u> , Abstract Citation Number 466219; only Abstract supplied.
* W†	Drago et al., "Memory Deficits of Aged Male Rats Can Be Improved by Pyrimidine Nucleosides and N-Acetylglutamine," <u>Clinical Neuropharmacology</u> , <u>13</u> (4), 290-296 (1990); <u>Biological Abstracts</u> , <u>90</u> , Abstract No. 91117 (1990); only Abstract supplied.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.


EXAMINER L. Eric Crane 	DATE 11/26/01	page 2 of 3 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number 09/363,748	Group Art Unit 1623	Attachment to Paper Number	20
Notice of References Cited	APPLICANT(S)			
	Watkins et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	X†	Manna et al., "Effects of Short-Term Administration of Cytidine, Uridine and L-Glutamine Alone or in Combination on the Cerebral Electrical Activity of Patients with Chronic Cerebrovascular Disease," <u>Intl. Journal Clinical Pharmacology Research</u> , <u>8</u> (3), 199-210 (1988); <u>Biological Abstracts</u> , <u>86</u> , Abstract No. 51989 (1988); only Abstract supplied.
*	Y†	Keilbaugh et al., "Anti-Human Immunodeficiency Virus Type 1 Therapy and Peripheral Neuropathy: Prevention of 2', 3'-Dideoxycytidine Toxicity in PC12 Cells, a Neuronal Model, by Uridine and Pyruvate," <u>Molecular Pharmacology</u> , <u>44</u> (4), 702-706 (1993); <u>BIOSIS</u> , 1994, Abstract Citation Number 413648; only Abstract supplied.
*	Z†	Popov et al., "Protective Effect of Uridine on D-Galactosamine-Induced Deficiency in Brain Uridine Phosphates," <u>Biomedica Biochimica Acta</u> , <u>43</u> (12), 1399-1404 (1984; rec'd 1985); <u>Biological Abstracts</u> , <u>80</u> , Abstract No. 34525 (1985); only Abstract supplied.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. Eric Crane 	DATE 11/26/01	page 3 of 3 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		